Chitin-Derived AVR-48 Prevents Experimental Bronchopulmonary Dysplasia (BPD) and BPD-Associated Pulmonary Hypertension in Newborn Mice
Authors:
- Pragnya DasPDPragnya Das
- Suchismita AcharyaSuchismita Acharya
- Varsha M. PrahaladanVarsha M. Prahaladan
- Ogan K. KumovaOKOgan K. Kumova
- Shadi MalaebSMShadi Malaeb
- Sumita BeheraSBSumita Behera
- Beamon AgarwalBABeamon Agarwal
- Dale J. ChristensenDCDale J. Christensen
- Alison J. CareyACAlison J. Carey
- Vineet BhandariVineet Bhandari
Open Access
- 9 August 2021
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (16) , 8547
Abstract
Bronchopulmonary dysplasia (BPD) is the most common complication of prematurity and a key contributor to the large health care burden associated with prematurity, longer hospital stays, higher hospital costs, and frequent re-hospitalizations of affected patients through the first year of life and increased resource utilization throughout childhood. This disease is associated with abnormal pulmonary function that may lead to BPD-associated pulmonary hypertension (PH), a major contributor to neonatal mortality and morbidity. In the absence of any definitive treatment options, this life-threatening disease is associated with high resource utilization during and after neonatal intensive care unit (NICU) stay. The goal of this study was to test the safety and efficacy of a small molecule derivative of chitin, AVR-48, as prophylactic therapy for preventing experimental BPD in a mouse model. Two doses of AVR-48 were delivered either intranasally (0.11 mg/kg), intraperitoneally (10 mg/kg), or intravenously (IV) (10 mg/kg) to newborn mouse pups on postnatal day (P)2 and P4. The outcomes were assessed by measuring total inflammatory cells in the broncho-alveolar lavage fluid (BALF), chord length, septal thickness, and radial alveolar counts of the alveoli, Fulton’s Index (for PH), cell proliferation and cell death by immunostaining, and markers of inflammation by Western blotting and ELISA. The bioavailability and safety of the drug were assessed by pharmacokinetic and toxicity studies in both neonatal mice and rat pups (P3-P5). Following AVR-48 treatment, alveolar simplification was improved, as evident from chord length, septal thickness, and radial alveolar counts; total inflammatory cells were decreased in the BALF; Fulton’s Index was decreased and lung inflammation and cell death were decreased, while angiogenesis and cell proliferation were increased. AVR-48 was found to be safe and the no-observed-adverse-effect level (NOAEL) in rat pups was determined to be 100 mg/kg when delivered via IV dosing with a 20-fold safety margin. With no reported toxicity and with a shorter half-life, AVR-48 is able to reverse the worsening cardiopulmonary phenotype of experimental BPD and BPD-PH, compared to controls, thus positioning it as a future drug candidate.Keywords
Funding Information
- AyuVis Research Inc (Contract Research)
This publication has 56 references indexed in Scilit:
- Negative regulation of Toll-like receptor 4 signaling by IL-10–dependent microRNA-146bProceedings of the National Academy of Sciences, 2013
- A Critical Regulatory Role for Macrophage Migration Inhibitory Factor in Hyperoxia-Induced Injury in the Developing Murine LungPLOS ONE, 2013
- Chitohexaose Activates Macrophages by Alternate Pathway through TLR4 and Blocks EndotoxemiaPLOS Pathogens, 2012
- Neonatal Hyperoxia Causes Pulmonary Vascular Disease and Shortens Life Span in Aging MiceThe American Journal of Pathology, 2011
- Pulmonary Dendritic Cells in Lungs of Preterm Infants: Neglected Participants in Bronchopulmonary Dysplasia?Pediatric and Developmental Pathology, 2011
- Developmental Regulation of NO-Mediated VEGF-Induced Effects in the LungAmerican Journal of Respiratory Cell and Molecular Biology, 2008
- Hyperoxia causes angiopoietin 2–mediated acute lung injury and necrotic cell deathNature Medicine, 2006
- Type II epithelial cells are critical target for hyperoxia-mediated impairment of postnatal lung developmentAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2006
- Developmental differences in the role of interleukins in hyperoxic lung injury in animal modelsFrontiers in Bioscience-Landmark, 2002
- The radial alveolar count method of Emery and Mithal: a reappraisal 1--postnatal lung growth.Thorax, 1982